echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Hanyu Pharmaceutical Co., Ltd. has accepted the raw materials and preparations of ticlopeptide and nesiritide

    Hanyu Pharmaceutical Co., Ltd. has accepted the raw materials and preparations of ticlopeptide and nesiritide

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to the website of the State Food and Drug Administration (CFDA) on March 27, Hanyu Pharmaceutical Co., Ltd

    centrally applied for the acceptance of the three kinds of clinical drugs, i.e

    the raw materials and preparations of ticarciptide and nesiritide, to further reserve varieties of polypeptide drugs for the company

    Nesiritide and nesiritide for injection are cardiovascular drugs

    They are recombinant human B-type natriuretic peptide developed by scios company of the United States

    They are mainly used for the treatment of dyspnea in acute decompensated congestive heart failure

    Another declared variety, ticlopidine and ticlopidine zinc suspension injection, belongs to the category of endocrine drugs, which can stimulate the adrenal cortex to secrete corticosteroids

    Hanyu Pharmaceutical Co., Ltd

    is the first listed company dealing in polypeptide drugs in China, with the market share ranking top three

    The company's polypeptide preparations mainly include thymopentin for injection, somatostatin for injection and deammopressin acetate injection

    According to the 2013 annual report, the company's main business income was 301 million yuan, an increase of 33.37% year on year, and the net profit attributable to shareholders of the listed company was 129 million yuan, an increase of 44.69% year on year

    During the period, the company's main polypeptide preparation revenue reached 269 million yuan, an increase of 29.47%, accounting for nearly 90% of the main revenue

     
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.